Viewing data from:

HUMATIN

ANDA

PAROMOMYCIN SULFATE | A060521 | PARKEDALE PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Humatin (2023)

Total Spending

$421K

Total Claims

Beneficiaries

Avg Cost/Unit

$102.33

Spending Trend

$74K(2022)→$421K(2023)

YoY Change:+38.0%

5yr CAGR:+38.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

OLON SPAPAROMOMYCIN SULFATE

DMF 135761998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 250MG BASE

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.